Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features

Journal of Affective Disorders

Volumn 58, Issue 1, 2000, Pages 1-10

  Zaharia, Marilee D ^a   Ravindran, Arun V ^b   Griffiths, Jenna ^b   Merali, Zul ^b,c   Anisman, Hymie ^a,b  

^a CARLETON UNIVERSITY   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Dysthymia; Immune; Lymphocyte proliferation; Major depression; Neurovegetative features

Indexed keywords

ANTIDEPRESSANT AGENT; CONCANAVALIN A; FLUOXETINE; MITOGENIC AGENT; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHYTOHEMAGGLUTININ; PLACEBO; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DYSTHYMIA; EATING DISORDER; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SLEEP DISORDER; SYMPTOM;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DYSTHYMIC DISORDER; FEMALE; FLUOXETINE; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PAROXETINE; PERSONALITY INVENTORY; SERTRALINE;

EID: 0034175941     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(99)00100-7     Document Type: Article

References (34)

1. Akiskal H.S. Towards a definition of dysthymia: boundaries with personality and mood disorders. Burton S.W., Akiskal H.S., Dysthymic Disorders. 1990;1-12 Gaskell, London.
2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed :1994;American Psychiatric Association, Washington.
3. Anisman H., Merali Z., Griffiths J., Ravindran A.V. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol. Psychiatry. 4:1999;182-188.
4. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry. 4:1961;561-569.
5. Beck, A.T., Beck, R.W., 1972. Screening depressed patients in family practice a rapid technique, Postgrad. Med. December, 81-85.
6. Calabrese J.R., Kling M.A., Gold P.W. Alterations in immunocompetence during stress, bereavement, and depression: focus on neuroendocrine regulation. Am. J. Psychiatry. 144:1987;1123-1134.
7. Cosyns P., Maes M., Vanderwoude M., Stevens W.J., De Clerck L.S., Schotte C. Impaired mitogen-induced lymphocyte responses and the hypothalamic-pituitary-adrenal axis in depressive disorders. J. Affect. Disord. 16:1989;41-48.
8. De Goeij D.C.E., Jezova D., Tilders F.J.H. Repeated stress enhances vasopressin synthesis in corticotropin releasing factor neurons in the paraventricular nucleus. Brain Res. 577:1992;165-168.
9. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1976;National Institute for Mental Health, Psychopharmacology Research Branch, Bethesda, MD.
10. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 32:1967;50-55.
11. Herbert T.B., Cohen S. Depression and immunity: A meta-analytic review. Psychol. Bull. 113:1993;472-486.
12. Howland R.H., Thase M.E. Biological studies of dysthymia. Biol. Psychiatry. 30:1991;283-304.
13. Irwin M., Lacher U., Caldwell C. Depression and reduced natural killer cytotoxicity: a longitudinal study of depressed patients and control subjects. Psychol. Med. 22:1992;1045-1050.
14. Irwin M., Mascovich A., Gillin J.C., Willoughby R., Pike J., Smith T.L. Partial sleep deprivation reduces natural killer cell activity in humans. Psychosom. Med. 56:1994;493-498.
15. Irwin M., Smith T.L., Gillin J.C. Low natural killer cytotoxicity in major depression. Life. Sci. 41:1987;2127-2133.
16. Kronfol Z., House J.D. Depression, cortisol and immune function. Lancet. 1:1984;1026-1027.
17. Maes M. Evidence for an immune response in major depression: A review and a hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;11-38.
18. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E., Ranjan R., et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2, and tranferrin receptor in major depression. J. Affect. Disord. 34:1995;301-309.
19. Maes M., Stevens W., Peeters D., DeClerck L., Scharpe S., Bridts C., et al. A study on the blunted natural killer cell activity in severely depressed patients. Life Sci. 50:1992;505-513.
20. Miller A.H., Spencer R.L., McEwen B.S., Stein M. Depression, adrenal steroids, and the immune system. Ann. Med. 25:1993;481-487.
21. Moldofsky H. Sleep and the immune system. Int. J. Immunopharm. 17:1995;649-654.
22. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 134:1979;382-389.
23. O'Leary A. Stress, emotion and human immune function. Psychol. Bull. 108:1990;363-382.
24. Ravindran A.V., Griffiths J., Merali Z., Anisman H. Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features. Psychosom. Med. 60:1998;283-289.
25. Ravindran A.V., Griffiths J., Zaharia M., Merali Z., Anisman H. Immune and Endocrine Alterations in Atypical Depression. 1997;World Congress of Biological Psychiatry, Nice, France.
26. Ravindran A.V., Merali Z., Anisman H. Dysthymia: a biological perspective. Licinio J., Bolis C.L., Gold P., Dysthymia: From Clinical Neuroscience to Treatment. 1997;21-44 World Health Organization, Geneva.
27. Ravindran A.V., Griffiths J., Merali Z., Anisman H. Lymphocyte subsets associated with major depression and dysthymia: modification by antidepressant treatment. Psychosom. Med. 57:1995;555-563.
28. Schleifer S.J., Keller S.E., Meyerson A.T., Raskin M.J., Davis K.L., Stein M. Lymphocyte function in major depressive disorder. Arch. Gen. Psychiatry. 41:1984;484-486.
29. Schmidt E.D., Janszen A.W.J.W., Wouterlood F.G., Tilders F.J.H. Interleukin-1-induced long-lasting changes in hypothalamic corticotropin-releasing hormone (CRH)-neurons and hyperresponsiveness of the hypothalamic-pituitary-adrenal axis. J. Neurosci. 15:1995;7417-7426.
30. Sheehan D., Lecrubier Y., Janavs J., Knapp E., Weiller E., Sheehan M., et al. Mini-international Neuropsychiatric Interview. 1992;. Clinician Rated. Version 2.1.
31. Sluzewska A., Rybakowski J.K., Laciak M., Mackiewicz A., Sobieska M., Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. NY Acad. Sci. 762:1995;474-476.
32. Syvalahti E., Eskola J., Ruuskanen O., Laine T. Nonsuppression of cortisol in depression and immune function. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 9:1985;14-22.
33. Tilders F.J.H., Schmidt E.D., De Goeij D.C.E. Phenotypic plasticity of CRF neurons during stress. Ann. NY Acad. Sci. 697:1993;39-52.
34. Weisse C.S. Depression and immunocompetence: a review of the literature. Psychol. Bull. 111:1992;475-489.